#22096
Re: Novavax (NVAX): Un Nuevo Comienzo
The company was working to submit safety data on Novavax’s use as a booster to the TGA, he said, with hopes that an approval could be secured within weeks.
También destacable en mi opinión.
The company was working to submit safety data on Novavax’s use as a booster to the TGA, he said, with hopes that an approval could be secured within weeks.
2. Las mentiras constantes que siguen a día de hoy.
3. La falta de transparencia siempre es porque algo, mucho o poco, no va bien.
4. La ocultación/mentiras de cuantas dosis hay y cuantas se están haciendo a dia de hoy.
Executives initiated a second phase 3 trial for its RSV candidate despite a previous failed phase 3 trial and with knowledge another antigenic site elicited a significantly greater immune response.
Flu candidate didn’t demonstrate superiority to a FDA approved product. If approved it is unlikely to achieve significant market share.
Delays for its Covid-19 vaccine have allowed competitors to take significant market share.
With the exception of its flu candidate, Novavax has no near-term prospects in its pipeline making it dependent on Covid-19.
The plant has produced 60 million doses of the Novavax vaccine, which is being used in other countries but is still waiting approval in the UK.
Fuji fabrica el antígeno y GSK en UK se encarga del Fill and Finish.
Solo falta la validación final de ese proceso.